Development of Biologics in China for Global Markets: Lessons From Wuhan, China

• Discussing the approach required to success in the unique business environment of the region
• Walking through recent changes in the regulatory and operating environment in China
• Offering lessons learned by JHL Biotech, a biologics development and manufacturing firm with headquarters in Taiwan and a commercial-scale production site in Wuhan, China
• Highlighting JHL Biotech’s path to rapidly building and operating two production facilities in Asia, with an emphasis on JHL’s use of modular and single-use technologies to accelerate facility construction and accelerate product timelines

—

Racho Jordanov
CEO & Co-Founder
JHL Biotech Inc.

Racho Jordanov is Co-Founder, President, and CEO of JHL Biotech, a biologics development and manufacturing firm headquartered in Hsinchu, Taiwan. Mr. Jordanov started his biopharma career at Genentech in 1981, where he became a leader in technical operations. In addition, Mr. Jordanov has held senior leadership positions at Serono, Cholestech, and Telios Pharmaceuticals. Mr. Jordanov earned his B.S. in chemical engineering from the University of California, San Diego and his M.B.A. from National University, San Diego.